Table V.

Virus-specific CD8+ T cell response in subject AC10

PeptideAmino Acid SequenceSFC/106 Cells at Daya
−34458119144227295445515667734825873923
Gag
2SGGELDRWEKIRLRPGGK020300100000401030 260 170
4GKKKYKLKHIVWASRELb00000000000000
11TGSEELRSLYNTVATLYc0204001000 60 ND ND 180 260 890 480
12SLYNTVATLCVHQRIEVc0103000200 110 320 400 320 90 900 750
24PMFSALSEGATPQDLNTM000002000300020030
28LKETINEEAAEWDRLHPV04000100402000010 170 330
40GPKEPFRDYVDRFYKTLR100100104020 60 NDND 60 100 200
58QMKDCTERQANFLGKIWc00005010 80 50 220 240 300 130 450 310
59RQANFLGKIWPSHKGRc0201000 70 120 250 350 459 480 230 610 540
63TAPPEESFRFGEETTTPSQK10030000301030 60 30 200 500 490
Nef
71DGVGAVSRDLEKHGAI101010001020 180 320 180 280 100 280 180
79SHFLKEKGGLEGLIYSQK1020200010 110 200 550 680 680 970 1420 1410
84NYTPGPGIRYPLTFGWCFc101020020100200 240 430 150 980 800
85RYPLTFGWCFKLVPVc2010305010400020 400 590 350 1060 590
88EANEGENNSLLHPMSLH05050402050 110 0 180 440 490 220 1100 1030
90SLHGMDDPEKEVLVWKFc40050 60 90 160 370 260 390 370 320 250 600 520
91PEKEVLVWKFDSRLAFHHc204050200 180 300 270 360 410 380 150 350 340
93AFHHMARELHPEYYKDC102020101030 170 80 420 410 440 310 850 540
Pol
152GTVSESFPQITLWQRPLV0050000001010 90 10 410 390
194KIEELRQHLLRWGFTTPDK010002000000004020
271YYRDSRDPLWKGPAKLLW40 110 240 240 260 470 740 660 690 770 740 810 1450 1310
Vpr
283SLGQHIYETYGDTWAGV 80 120 220 150 130 110 570 660 660 800 850 670 1110 940
Env
296LFCASDACAYDTEVHNVWc10502000200501020 80 40 510 390
297AYDTEVHNVWATHACVc10205000105001040 160 130 420 430
302WKNNMVEQMHEDIISLWc40205004050 70 280 800 960 770 820 1240 960
303QMHEDIISLWDQSLKPCVc20102002030 80 140 690 680 820 310 870 650
366RVLAVERYLKDQQLLGIW1000000030030 60 90 170 130
374NYTSLIYTLIEESQNQQEK50000102001010 70 70 20 230 180
398AVAEGTDRVIEVVQRACR10 80 70 0 80 0010 300 420 210 80 170 270
Vif
413VSIEWRKKRYSTQVDPDLc103010010200010 100 150 230 680 600
414RYSTQVDPDLADQLIHLYc1010 70 00100030 150 230 230 360 550
Optimal CD8 epitopes
A2-SL9 (p17)SLYNTVATL10100000 150 240 680 720 610 760 970 1110
A24-RW8 (env)RYLKDQQLL1010300200000050 530 1200 130
A24-KW9 (p17)KYKLKHIVW202020 80 90 130 340 140 ND ND ND 190 100 140
B60-SL9 (p24)SEGATPQDL200200030010204001050 80
B60-IL9 (RT)IEELRQHLL00020010000102020 80 10
B60-KL9 (Nef)KEKGGLEGL0010010100 280 0 ND 480 690 >1000 >1000
Totals80310600530650112032103870685889591027090502139017740
  • a IFN-γ-producing cells at the indicated number of days after treatment cessation. A total of 410 overlapping peptides (17–19 mers) spanning the entire expressed HIV-1 clade B consensus sequence as well as 28 peptides corresponding to optimal CTL epitopes described for the study subject’s HLA class I type (A2/24 B38/60, Cw2/12) were tested. Only peptides that induced significant responses (>50 SFC/106 PBMC above background and three times above mean background activity) at least at one time point are shown (positive responses are in italics and boldface). Targeted described optimal CTL epitopes within overlapping peptides are shown in boldface type. nd, not determined.

  • b Overlapping peptides that contained described recognized optimal CTL epitopes, but were not recognized themselves, are shown. These responses represented low magnitude CD8+ T cell responses only detectable using the optimal epitope sequence.

  • c Responses to two overlapping peptides may contain the same CD8+ T cell epitope in their overlap and were therefore counted as one CD8+ T cell response in the analysis.